The availability of specialized maternal mental health care varies significantly by geography, with North America and Europe currently leading the way in the adoption of PPD-specific drugs. In these regions, high awareness and advanced healthcare infrastructure have made it possible for many women to access the latest treatments. However, a deep dive into each Postpartum Depression Drug Market...

According to a new report from Intel Market Research, the global Esketamine market was valued at USD 1.05 billion in 2025 and is projected to reach USD 2.15 billion by 2034, growing at a CAGR of 7.8% during the forecast period (2026–2034). This growth is driven by rising mental health awareness, increasing prevalence of treatment-resistant depression, and expanding therapeutic...

"Comprehensive Outlook on Executive Summary Pharmacogenetics Testing in Psychiatry/Depression Market Size and Share CAGR Value The global pharmacogenetics testing in psychiatry/depression market size was valued at USD 1.34 billion in 2024 and is expected to reach USD 2.97 billion by 2032, at a CAGR of 10.4% during the forecast period The insights...

Productivity and Mental Health Mental health is no longer just a medical issue; it's a massive economic one. Depression is the leading cause of disability worldwide. The cost to the global economy is estimated in the trillions, primarily due to "Presenteeism"—when employees are at work but not fully functional. This economic reality is forcing insurance companies and governments to...

The financial commitment to mental health infrastructure has seen a dramatic increase as governments recognize the high cost of untreated depression on national productivity. Absenteeism and "presenteeism"—where employees are physically at work but mentally checked out—cost the global economy trillions of dollars annually. Consequently, public and private sectors are funneling...